ResMed Inc (ASX:RMD) director Jan De Witte sold 429 shares of ResMed common stock at a price of $237 per share on 17 November 2026, according to a Statement of Changes in Beneficial Ownership filed with the United States Securities and Exchange Commission.

Key Points

  • Director Jan De Witte disposed of 429 shares of ResMed common stock on 17 November 2026 at $237 per share
  • Following the transaction, De Witte directly holds 3,772 shares of ResMed common stock
  • The sale was conducted under a Rule 10b5-1 trading plan adopted on 19 August 2026
  • The filing was signed by Jan De Witte on 18 November 2026

Transaction Details for the 17 November 2026 Share Sale

According to the SEC Form 4 filing, Jan De Witte, a director of ResMed Inc, disposed of 429 shares of ResMed common stock on 17 November 2026 at a price of $237 per share. The transaction is classified as a direct ownership disposal under the filing. No derivative securities were acquired or disposed of in connection with this reported transaction. The filing was submitted pursuant to Section 16(a) of the Securities Exchange Act of 1934, which requires reporting persons who are directors or officers to disclose changes in their beneficial ownership of issuer securities.

Post-Transaction Beneficial Ownership Position

Following the reported sale, Jan De Witte directly holds 3,772 shares of ResMed common stock, as disclosed in Table I of the Form 4 filing. The filing records no indirect beneficial ownership of ResMed common stock by De Witte and no derivative securities positions, including options, warrants or convertible securities, as reflected in Table II of the form. De Witte is identified in the filing as a director of ResMed Inc, with an address care of ResMed Inc at 9001 Spectrum Center Boulevard, San Diego, California 92123.

Rule 10b5-1 Trading Plan Adopted 19 August 2026

The filing states that the share sale was conducted pursuant to a Rule 10b5-1 trading plan adopted by Jan De Witte on 19 August 2026. The filing indicates the transaction satisfies the affirmative defence conditions of Rule 10b5-1(c), as denoted by the corresponding checkbox on the Form 4. Rule 10b5-1 plans allow company insiders to establish pre-scheduled trading arrangements at a time when they are not in possession of material non-public information. The Form 4 was signed by Jan De Witte in his capacity as director and filed with the SEC on 18 November 2026.